At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,460 enrolled
Drug / intervention
Sublingual allergy immunotherapy tablet +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A One-year Placebo-controlled Phase III Trial Evaluating the Efficacy and Safety of the House Dust Mite (HDM) SLIT-tablet in Children (5-11 Years of Age) With HDM Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma
In Brief
A Phase 3 clinical trial evaluating Sublingual allergy immunotherapy tablet and Placebo for Allergic Rhinitis Due to Dermatophagoides Farinae and 2 related conditions. Completed, enrolled 1,460 participants across 113 sites in 11 countries.
Detailed Summary
A research study of how house dust mite tablets work compared to placebo in children aged between 5 and 11 years and who have allergy to house dust mites (MATIC)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
CountriesBulgaria, Canada, France, Germany, Lithuania, Poland, Russia, Slovakia, Spain, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartOct 2019
First PostedOct 2019
Primary CompletionApr 2023
Study CompletionApr 2023
TodayJul 2026
First PostedOct 30, 2019
Enrollment StartOct 12, 2019
Primary CompletionApr 1, 2023
Study CompletionApr 21, 2023
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 6.7 years ago
Interventions
Sublingual allergy immunotherapy tabletbiological
For daily administration (1 tablet per day)
Placeboother
For daily administration (1 tablet per day)